Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 4/20 | 0.43 |
| ▸ | CES1 | P23141 | 4/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | ALPI | P09923 | 1/20 | 0.33 |
| ▸ | ALPG | P10696 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7139876 | 0.82 | GAA (0.41) | GAACES2CES1EPHX2FSCN1 | |
| SCHEMBL30661239 | 0.72 | GAA (0.33) | GAA | |
| SCHEMBL24534986 | 0.71 | FSCN1 (0.47) | CES2CES1EPHX2FSCN1BCHE | |
| SCHEMBL22067650 | 0.70 | CES2 (0.36) | CES2CES1EPHX2 | |
| SCHEMBL7695978 | 0.70 | EPHX2 (0.40) | GAACES2CES1EPHX2ALPL | |
| SCHEMBL8790100 | 0.69 | CES2 (0.34) | GAACES2CES1EPHX2FSCN1 | |
| SCHEMBL16859740 | 0.69 | CES2 (0.42) | CES2CES1EPHX2RIPK1ALPL | |
| SCHEMBL2334833 | 0.68 | EPHX2 (0.43) | CES2CES1EPHX2RIPK1ALPL | |
| SCHEMBL135331 | 0.67 | CES2 (0.37) | CES2CES1EPHX2 | |
| SCHEMBL21513960 | 0.67 | GAA (0.70) | GAACES2CES1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354922-B2 | Bridged ring NK1 antagonists | SCHERING CORPORATION (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1828188-A1 | BRIDGED RING NK1 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060258665-A1 | Bridged ring NK1 antagonists | SCHERING CORPORATION | 2006-11-16 | — | — | US | disclosed |
| WO-2006065654-A1 | BRIDGED RING NK1 ANTAGONISTS | SCHERING CORPORATION (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258665-A1 | Bridged ring NK1 antagonists | GRPR, BDKRB2, NPSR1 | GAA 2359/4885CES2 4189/4885CES1 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.